What it's for (Indications)
- Midazolam is indicated for sedation before and during minor surgical procedures, induction of anesthesia, and for the treatment of disturbances of sleep rhythm and all forms of insomnia.
- It is also used for sedation in non-critical care settings and during procedures involving the airway, such as upper endoscopy and dental procedures.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Midazolam injection is a potent sedative agent that requires slow administration and individualization of dosage. Clinical experience indicates that midazolam hydrochloride is 3 to 4 times as potent per mg as diazepam. Because serious and life-threatening cardiorespiratory adverse events have been reported, provision for monitoring, detection, and correction of these reactions must be made for every patient to whom midazolam injection is administered, regardless of age or health status. Excessive single doses or rapid intravenous administration may result in respiratory depression, airway obstruction, and/or arrest. The potential for these latter effects is increased in debilitated patients, those receiving concomitant medications capable of depressing the CNS, and patients without an endotracheal tube but undergoing a procedure involving the upper airway such as endoscopy or dental procedures. |
Safety & Warnings
Common Side Effects
- Common side effects include increased confusion, hallucinations, headache, somnolence (sleepiness), dizziness, ataxia, anterograde amnesia, gastrointestinal upset, hypotension (low blood pressure), rash, slight tachycardia (high heart rate), vasodilation (widening of blood vessels), dyspnoea (difficulty in breathing), thrombophlebitis (blood clots forming in the legs), and pain at the injection site.
- Fluctuations in vital signs are frequently observed, including decreased tidal volume and/or respiratory rate, apnea, and variations in blood pressure and pulse rate.
- Serious cardiorespiratory events and possible paradoxical reactions have been reported, with a higher incidence in patients receiving concomitant central nervous system depressants or those undergoing airway procedures without an endotracheal tube.
Serious Warnings
- Black Box Warning: WARNINGS Personnel and Equipment for Monitoring and Resuscitation Adults and Pediatrics: Intravenous midazolam hydrochloride has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. In some cases, where this was not recognized promptly and treated effectively, death or hypoxic encephalopathy has resulted. Intravenous midazolam hydrochloride should be used only in hospital or ambulatory care settings, including physici
- Midazolam carries a positive evidence of risk during pregnancy; therefore, consultation with a doctor is advised.
- The effect of this medicine is undetermined in lactating females, and medical advice should be sought.
- Patients should avoid driving and consuming alcohol due to potential impairment.
- Precautions are necessary for individuals with chronic respiratory insufficiency, renal, hepatic, or cardiac impairment.
- Pediatric patients with heart impairment should receive lower doses, and vital functions must be monitored.
- Caution is advised for patients with a history of alcohol or drug abuse, Myasthenia Gravis, and in elderly patients.
- Due to the potential for serious and life-threatening cardiorespiratory adverse events, provision for continuous monitoring, detection, and correction of these reactions must be made for every patient.
- Excessive single doses or rapid intravenous administration can lead to respiratory depression, airway obstruction, and/or arrest, with an increased risk in debilitated patients, those on concomitant CNS depressants, or during upper airway procedures without an endotracheal tube.
How it Works (Mechanism of Action)
Midazolam is a potent, short-acting benzodiazepine that exerts its primary pharmacological effects through allosteric modulation of the gamma-aminobutyric acid type A (GABA-A) receptor complex in the central nervous system (CNS). GABA is the principal inhibitory neurotransmitter in the brain, and the GABA-A receptor is a ligand-gated chloride ion channel. Midazolam binds specifically to a distinct benzodiazepine recognition site on the GABA-A receptor, which is typically located between the alpha (α) and gamma (γ) subunits. This binding does not directly open the chloride channel, but rather enhances the affinity of GABA for its own binding site on the receptor. Consequently, in the presence of GABA, midazolam increases the *frequency* of chloride channel opening. The subsequent influx of negatively charged chloride ions into the neuron leads to hyperpolarization of the neuronal membrane, thereby reducing neuronal excitability and inhibiting synaptic transmission. This generalized CNS depression manifests clinically as anxiolysis, sedation, hypnosis, anterograde amnesia, anticonvulsant activity, and skeletal muscle relaxation. The rapid onset and relatively short duration of action of midazolam are attributed to its high lipophilicity, which allows for quick penetration of the blood-brain barrier, and its subsequent rapid redistribution from the CNS to peripheral tissues, followed by hepatic metabolism.
Commercial Brands (Alternatives)
No other brands found for this formula.